Comparative Pharmacology
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 350.
GASTROGRAFIN vs OMNIPAQUE 350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
Radiopaque agent: iodine-containing contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. Non-ionic, low-osmolar agent.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
1-2 mL/kg IV up to 150 mL for CT; 30-50 mL IV for DSA; max 350 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. May be prolonged in renal impairment.
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Primarily renal excretion via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent